University of Maryland Medical Center

Marlene and Stewart Greenebaum Comprehensive Cancer Center

Baltimore, MD

Accepting patients

CAMMA-2

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma (CAMMA 2)
Learn more
  • Bispecific Antibody
  • FCRH5
  • Phase 1/2

Accepting patients

DREAMM13

A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function
Learn more
  • Antibody Drug Conjugate (ADC)
  • BCMA
  • Phase 1
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials

Accepting patients

DREAMM12

A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Participants With Normal and Varying Degrees of Impaired Renal Function
Learn more
  • Antibody Drug Conjugate (ADC)
  • BCMA
  • Phase 1

Not yet accepting

CARTITUDE-6

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)
Learn more
  • Autologous Stem Cell Transplant
  • CAR T Cell
  • BCMA
  • Phase 3

Accepting patients

iMMAGINE-1

Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma
Learn more
  • CAR T Cell
  • BCMA
  • Phase 2

Accepting patients

P-BCMA-ALLO1

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (MM)
Learn more
  • CAR T Cell (Allogeneic)
  • BCMA
  • Phase 1